Loutfi I, Batchelor J R, Chisholm P M, Epenetos A A, Lavender J P
Department of Nuclear Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Nucl Med Commun. 1988 Oct;9(10):787-96. doi: 10.1097/00006231-198810000-00017.
In this paper, we emphasize the rationale and work-up studies for using two radiolabelled anti-lymphocyte monoclonal antibodies for in vivo application as radiolabelling agents for T and B cells. In vitro experimental work involved radioimmunoassays on human lymphoid cell lines and anticoagulated whole blood with identification of relevant binding kinetics in terms of antibody internalization and elution. We tested also for the effect of the radiolabelled monoclonal antibodies on in vitro cell function defined as mitogen-induced proliferation in whole blood. As a final work-up in an animal model, the distribution of both unlabelled and 111In-labelled anti-Pan T cell monoclonal antibody was studied in the rat. Results from the in vitro experiments pointed to the possibility of using the described technique for specific lymphocyte radiolabelling. The in vivo application enabled us to identify optimal doses of antibody and radioactivity which showed agreement with the in vitro data.
在本文中,我们强调了使用两种放射性标记的抗淋巴细胞单克隆抗体作为T细胞和B细胞的放射性标记剂进行体内应用的基本原理和检查研究。体外实验工作包括对人淋巴细胞系和抗凝全血进行放射免疫测定,确定抗体内化和洗脱方面的相关结合动力学。我们还测试了放射性标记单克隆抗体对体外细胞功能的影响,该功能定义为全血中丝裂原诱导的增殖。作为动物模型的最终检查,研究了未标记和111In标记的抗全T细胞单克隆抗体在大鼠体内的分布。体外实验结果表明了使用所述技术进行特异性淋巴细胞放射性标记的可能性。体内应用使我们能够确定与体外数据一致的抗体最佳剂量和放射性剂量。